89bio to Present at Upcoming Investor Conference

Rhea-AI Summary

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that CEO Rohan Palekar will present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 11:30 AM ET. The event will be available via live and archived webcast on the company's website. 89bio is focused on developing innovative therapies for liver and cardio-metabolic diseases, with its lead product candidate, BIO89-100, targeting NASH and severe hypertriglyceridemia. The company is based in San Francisco and has operations in Israel.

SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will present at the H.C. Wainwright 4^th Annual NASH Investor Conference on Monday, October 5, 2020 at 11:30 AM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.89bio.com/events-and-presentations. The replay of the webcast will be available on the company’s website.

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Lori Rosen
LDR Communications
917-553-6808
lori@ldrcommunications.com

FAQ

When is 89bio's presentation at the H.C. Wainwright NASH Investor Conference?

89bio's presentation is scheduled for October 5, 2020, at 11:30 AM ET.

Where can I watch the webcast of 89bio's presentation?

The live and archived webcast can be accessed on 89bio's website.

What is BIO89-100 developed by 89bio?

BIO89-100 is a glycoPEGylated analog of FGF21 being developed for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.

What is the focus of 89bio, Inc.?

89bio focuses on developing therapies for liver and cardio-metabolic diseases.

What is 89bio's stock symbol?

The stock symbol for 89bio is ETNB.